The Fourth Annual International Frontiers in Cancer Prevention Research Conference took place from Sunday, October 30 to Wednesday, November 2, 2005 at the Baltimore Convention Center in Baltimore, Maryland. The conference provided a forum for basic scientists, translational researchers, physician-scientists, epidemiologists, and behavioral scientists from a variety of sectors in the cancer community to come together and focus on cancer prevention research. The program was enriched by a variety of session formats – educational sessions, concurrent sessions, plenary sessions, and a panel discussion as well as special professional advancement sessions for young investigators. There were unique opportunities for transdisciplinary interactions – a key hallmark of this conference and an essential element in making further progress in cancer prevention.
The Opening Plenary Session began with a Special Presentation by Andrew C. von Eschenbach, Director of the National Cancer Institute. This was followed by distinguished lectures by Bert Vogelstein of Johns Hopkins University and Arnold J. Levine of the Institute for Advanced Studies. Joseph Schlessinger presented the first Distinguished Lecture on Molecular Targets for Cancer Prevention.
The program consisted of 15 Educational Sessions, 4 Major Plenary Sessions, a "Best Abstracts" session, 22 Concurrent Sessions, 3 Poster Sessions, 2 Professional Advancement Series Sessions, a Panel Discussion, and the Fourth Annual American Association for Cancer Research – Cancer Research and Prevention Foundation Award for Excellence in Cancer Prevention Research Lecture by award recipient Scott M. Lippman.
This fourth annual multidisciplinary conference drew over 800 participants from more than 25 different countries representing academia, government, and industry. Nearly 350 proffered papers were presented that encompassed all of the sciences pertaining to cancer prevention - from linking the biology of the cancer process with its prevention and reversal in preinvasive stages to fostering translational research. The discussions, collaborations, and energies coming out of this conference provided new insights and perspectives on how to make further striking advances in the field, and also strengthened the vitally important partnership between basic, clinical, and behavioral cancer prevention researchers and leaders of the survivor advocacy organizations. Cancer prevention strategies are already making a difference in reducing incidence and mortality, and the future holds great promise and excitement for further breakthroughs.